Abstract
In 579 COVID patients’ samples collected between March and July of 2020, we examined the effects of non-synonymous mutations harbored by the circulating B.1.1.7 strain on linear antibody epitope signal for spike glycoprotein and nucleoprotein. At the antigen level, the mutations only substantially reduced signal in 0.5% of the population. Although some epitope mutations reduce measured signal in up to 6% of the population, these are not the dominant epitopes for their antigens. Given dominant epitope patterns observed, our data suggest that the mutations would not result in immune evasion of linear epitopes for a large majority of these COVID patients.
Competing Interest Statement
The authors declare the following competing interests: employment and personal financial interests including stock options at Serimmune, Inc: WAH, KK, JCS. Serimmune has submitted the following US Patent Application 63/114,939 SARS-CoV-2 Serum Antibody Profiling SUI-009PR4.
Funding Statement
No external funding was received. A.I. is an investigator of the Howard Hughes Medical Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Yale Cohort: Yale University IRB, Approved SBCH Cohort: Santa Barbara Cottage Health IRB (SBCH IRB), Waived (Human Subjects Exemption, de-identified remnant samples) BCA Cohort: New York Blood Center (NYBC) IRB, Waived (de-identified remnant samples) LabCorp Cohort: LabCorp clinical network IRB, Waived (de-identified remnant samples) BioIVT Cohort: BioIVT clinical network IRB, Waived (de-identified remnant samples)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available upon request.
